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Pfficacy and Safety of High-Density
ipoprotein Cholesterol-Increasing Compounds
Meta-Analysis of Randomized Controlled Trials
akesh S. Birjmohun, MD,* Barbara A. Hutten, PHD,† John J. P. Kastelein, MD, PHD,*
rik S. G. Stroes, MD, PHD*
msterdam, the Netherlands
OBJECTIVES The aim of this research was to estimate the efficacy and safety of current high-density
lipoprotein cholesterol (HDL-C)-increasing drugs.
BACKGROUND Epidemiologic evidence has shown that HDL-C is inversely related to coronary heart disease
(CHD) risk. However, the evidence for reducing CHD risk by raising HDL-C is thin,
predominantly due to the paucity of effective and safe HDL-increasing drugs.
METHODS Randomized controlled trials with fibrates and niacin, published between 1966 through
February 2004 (MEDLINE), were retrieved. Information on treatment, baseline character-
istics, serum lipids, end points, and side-effects were independently abstracted by two authors
using a standardized protocol.
RESULTS Data from 53 trials (16,802 subjects) using fibrates and 30 trials (4,749 subjects) using niacin
were included. Random-effects model showed 11% versus 10% reduction in total cholesterol,
36% versus 20% reduction in triglycerides, 8% versus 14% reduction in low-density
lipoprotein cholesterol, and 10% versus 16% increase in HDL-C for fibrates and niacin,
respectively. Apart from flushes in the niacin group, both fibrates and niacin were shown to
be well-tolerated and safe. Fibrates reduced the risk for major coronary events by 25% (95%
confidence interval 10% to 38%), whereas current available data for niacin indicate a 27%
reduction.
CONCLUSIONS Fibrates reduce major coronary events and increase HDL-C levels without significant
toxicity. Niacin has a more potent effect on HDL-C levels, whereas data on cardiovascular
event rate reduction are limited. Future studies need to evaluate whether additional HDL
increase by fibrates or particularly newer niacin formulations on top of statin therapy
translates into further event reduction in high-risk subjects, without significant
toxicity. (J Am Coll Cardiol 2005;45:185–97) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.031Cardiology Foundation
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ahe benefit of statins on cardiovascular (CV) end point
eduction in both primary and secondary settings has proven
o be a consistent finding throughout a large number of
andomized controlled trials. Recently, more intensive low-
ensity lipoprotein (LDL)-lowering was shown to be asso-
iated with a further reduction of CV events compared with
onventional lipid-lowering (1). However, it should be
oted that approximately 70% of CV events have not been
revented in statin trials (2). This staggering number has
ntensified the search for novel therapeutic targets. The
hoice of a new target has, to some extent, been directed by
he worldwide epidemic of obesity, metabolic syndrome,
nd type II diabetes mellitus (3), all characterized by a
on-LDL-cholesterol (C) dyslipidemia consisting of low
igh-density lipoprotein cholesterol (HDL-C) and in-
reased triglycerides (TG).
Large-scale population studies have demonstrated that
DL-C is a strong and independent inverse predictor of
oronary heart disease (CHD), even in subjects with normal
DL-C levels (4). Accordingly, up to 40% of patients with
remature CHD are characterized by low levels of HDL-C.
From the Departments of *Vascular Medicine and †Clinical Epidemiology and
iostatistics, Academic Medical Center of Amsterdam, Amsterdam, the Netherlands.a
Manuscript received May 10, 2004; revised manuscript received September 27,
004, accepted October 4, 2004.sing these data, it has been calculated that coronary risk
ncreases by 1% to 3% for every 1% reduction in HDL-C
evel. As a consequence, increasing HDL-C has emerged as
n attractive tool for CV prevention. In support, several
lasses of drugs with HDL-increasing effects have been
ssociated with reductions in CV event rates. Thus, fibrates,
hich mediate their HDL increase predominantly by per-
xisome proliferator agonist receptor-alpha activation, have
een shown to be associated with an absolute reduction in
rimary end points of 1.4% and 4.4% in primary (5) and
econdary (6) prevention, respectively. In line, nicotinic acid
erivatives, mediating HDL increase through a variety of
echanisms (7,8), have been associated with a reduction of
V events in one large monotherapy trial and two small
ombination secondary prevention trials (9,10). Unfortu-
ately, trials evaluating combination therapy of statins with
brates or niacin have been hampered because of safety
oncern.
As HDL-increasing interventions are expected to consti-
ute an important therapeutic option for CV prevention in
he next decade, we performed a meta-analysis of all random-
zed controlled trials using monotherapy of two currently
vailable classes of HDL-increasing compounds (fibric acid
nd nicotinic acid derivatives) in order to provide an accurate
nd precise estimate of their efficacy as well as their safety.
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ata sources and study selection. A literature search of
he MEDLINE database (1966 to February 2004) using the
edical subject headings fibric acid, fibrates, bezafibrate,
iprofibrate, clofibrate, etofibrate, fenofibrate, gemfibrozil,
icotinic acid, niacin, acipimox, controlled-release,
xtended-release, immediate-release, sustained-release, lip-
ds, lipoproteins, and CHD was performed. The search was
estricted to studies published in English-language journals,
onducted in humans, and classified as randomized con-
rolled trials. A manual search was also performed using the
uthors reference lists from randomized controlled trials and
eviews. For inclusion, studies had to meet the following
riteria: 1) random allocation of study participants to fi-
rates or niacin versus a control group or trials with a
rossover design; 2) changes in lipids; and 3) intervention
uration of 3 weeks. The most common reason for
xclusion of trials was missing values (mean or standard
eviation [SD]) for serum lipids.
ata abstraction. All data were abstracted independently
y two authors (R.B. and B.H.) in duplicate using a
tandardized protocol and reporting form. Disagreements
ere resolved by consensus. Authors were contacted for
dditional and missing information. When information of
ultiple doses and different treatment periods was available,
e selected the highest dose and the longest treatment
eriod for the calculations. Study characteristics recorded
ere as follows: 1) first author’s name, year of publication,
nd journal; 2) number of participants (n); 3) mean age,
ender, body mass index; 4) type and dosage of study drug;
) mean total cholesterol (TC), LDL-C, HDL-C, and TG
evels at baseline and follow-up; 6) adverse events; 7)
oronary end points; 8) treatment duration; and 9) dyslipi-
emia. Major coronary events recorded during long-term
reatment (2 years of active treatment) included coronary
eath (definite), nonfatal myocardial infarction, silent myo-
ardial infarction, coronary revascularization, unstable an-
ina, and sudden cardiac death. In addition, data were
bstracted on fatal CHD deaths, stroke, revascularization,
Abbreviations and Acronyms
CHD  coronary heart disease
CV  cardiovascular
ER  extended-release
HDL-C  high-density lipoprotein cholesterol
HHS  Helsinki Heart study
IR  immediate-release
LDL-C  low-density lipoprotein cholesterol
SD  standard deviation
SR  wax-matrix sustained-release
TC  total cholesterol
TG  triglycerides
VA-HIT  Veterans Affairs High-density lipoprotein
Intervention Trialon-CV deaths, cancer, and all-cause mortality during wreatment. Adverse events were divided in clinical adverse
vents and laboratory adverse events. Clinical adverse events
ere: serious adverse events, gastrointestinal symptoms
defined as abdominal pain, diarrhea, dyspepsia, nausea, and
omiting), skin reactions (defined as pruritus and/or rash),
ushes, and gout. Laboratory adverse events were hepato-
oxicity (defined as 3 times the upper limit of normal
erum glutamic oxalocetic transaminase/serum glutamic
yruvic transaminase value), musculoskeletal symptoms (de-
ned as 10 times the upper limit of normal creatine
hosphokinase value and/or myalgia), hyperglycemia (de-
ned as fasting glucose of 6.1 mmol/l or HbA1c 7%).
tatistical analysis. The data needed for the measurement
f the weighted mean difference were: 1) the mean change
n serum lipids (TC, TG, LDL-C, and HDL-C) from
aseline to follow-up in milligrams per deciliter (mg/dl); 2)
he SD of the mean difference; and 3) the number in each
omparison group (n) at follow-up (11).
The estimate of the principal effect was defined as the
ean difference in mg/dl between the change in lipid
oncentrations during active treatment (mean at follow-up
inus mean at baseline) and the change during the control
eriod (mean at follow-up minus mean at baseline). This
ifference is referred to as the net mean change. When the
Ddifference was not available in the source papers, authors
ere contacted. In case of no response or nonavailability of
he requested information, we estimated the variance with
he following formula (11):
Standard error (SE)difference
[SDbaseline2 ⁄ nbaseline SDfollow-up2 ⁄ nfollow-up]
The SDdifference was calculated from the SEdifference with the
ollowing formula:
SDdifference SEdifferencen
or the computation of pooled effects, each study was
ssigned a weight consisting of the reciprocal of its variance.
stimates of the average effect of fibrates or niacin on serum
ipids and 95% confidence intervals were calculated with
odels based on both fixed- and random-effects assump-
ions. Because substantial variability between observations
as indicated by preliminary tests for homogeneity, we have
resented the results of random-effects models calculated
ccording to the method of DerSimonian and Laird (12).
Relative risk reduction (RRR) and absolute risk reduction
ABR) were used to measure the effect of fibrates on clinical
utcomes. The numbers of various outcomes for both the
brate and control groups were recorded for each study
sing 2  2 tables.
The number of subjects in the treatment group in whom
n end point of interest was observed minus the number of
ubjects in the control group in whom an end point of
nterest was observed from each trial was summed, and z
tatistics were used to test whether the total differed from 0.
o calculate the pooled absolute risk, each study was
eighted by its sample size (Nt  Nc)/(Nt  Nc), (t 
t
(
o
d
s
i
h
g
W
T
w
L
2
c
F
T
a
t
L
h
b
R
S
fi
w
t
w
3
m
t
(
w
6
w
i
w
n
s
8
m
d
(
t
p
p
m
o
w
r
fi
T
d
w
w
t
6
(
7
2
h
a
5
d
h
a
E
s
L
T
m

a
T
c
b
b
(
m
(
d
(
d
i
B
a
L
g
L
d
i
r
e
c
m
1
g
(
F
o
s
(
s
A
i
j
i
187JACC Vol. 45, No. 2, 2005 Birjmohun et al.
January 18, 2005:185–97 Efficacy and Safety of HDL-C-Increasing Compoundsreatment; c  control). The number needed to treat
NNT) was calculated by taking the reciprocal of the ABR.
Subgroup analyses were performed to examine the effect
f fibrates and niacin on serum lipids in subjects with
ifferent dyslipidemias. First, the effects were compared in
ubjects with all lipid disorders, including secondary dyslip-
demia. Then we analyzed the effects in subjects with
ypercholesterolemia, combined hyperlipidemia, hypertri-
lyceridemia, low HDL-C, and type II diabetes mellitus.
e used the ATP-III classification to define lipid disorders.
rials classified as Frederickson’s type IIa hyperlipidemia or
ith mean baseline TC above 240 mg/dl, mean baselines
DL-C above 160 mg/dl, and without elevated TGs above
00 mg/dl were considered hypercholesterolemia. A trial was
onsidered combined hyperlipidemia if it was classified as
rederickson’s type IIb hyperlipidemia or with mean baseline
C above 160mg/dl, mean baseline LDL-C above 160mg/dl,
nd TG above 200 mg/dl. Trials classified as Frederickson’s
ype IV hyperlipidemia with normal mean baseline TC and
DL-C, but TG levels above 200 mg/dl, were considered as
ypertriglyceridemia. Trials with mean baseline HDL-C levels
elow 40 mg/dl were considered as low HDL-C.
ESULTS
tudy design and participants. The contents of 409 (275
brates and 134 niacin) abstracts or full-text manuscripts
ere reviewed to determine eligibility for inclusion. Because
rials with etofibrate were scarce, we excluded the only trial
ith this drug. A total of 83 trials (53 trials for fibrates and
0 trials for niacin) met our criteria and were included in the
eta-analysis (Tables 1 and 2). The distribution of the 53
rials with fibrates is as follows: 17 trials with gemfibrozil
5,6,13–27), 15 trials with fenofibrate (22,28–41), 13 trials
ith bezafibrate (22,42–53), 9 trials with clofibrate (21,54–
1), and 2 trials with ciprofibrate (62,63). For the 30 trials
ith niacin, the distribution is as follows: 11 trials with
mmediate-release niacin (IR-niacin) (54,64–73), 10 trials
ith acipimox (72,74–82), 6 trials with extended-release
iacin (ER-niacin) (67,83–87), and 5 trials with wax-matrix
ustained-release niacin (SR-niacin) (64,88–91). From the
3 trials, 6 trials (21,22,54,64,67,72) used multiple treat-
ent arms with more than one fibric acid or nicotinic acid
erivative, and 15 trials had different study populations
26,28,31,33,38,44,49,51,53,58,62,68,74,75,81). Overall, in
hese studies 16,802 subjects were treated with fibrates or
lacebo, and 4,749 subjects were treated with niacin or
lacebo. The average length of treatment was 12 and 8
onths for fibrates and niacin, respectively. The mean age
f patients taking fibrates or niacin was 56 and 58 years,
ith a male-to-female ratio of 16 to 1 and 7 to 1,
espectively. The body mass index of patients in trials with
brates and niacin was 27 and 28 kg/m2, respectively.
welve trials used random assignment with a crossover
esign (19,21,26,27,38,40,42,45,51,57,58,61). Subjects
ith the following dyslipidemias and study populations eere enrolled into the 83 trials: 29 trials with hypercholes-
erolemia (5,22–25,28,33,34,36,43,49,52,53,55–57,59,60,
2,64,67,85–90,92); 25 trials with type II diabetes mellitus
15,17,18,20,29,31,32,37–39,41,43,44,46,50,57,65,68,76–
9,81–83); 16 trials with combined hyperlipidemia (21,27,
8,33,38,44,49,51,58,62,63,69,72,74,75,80); 10 trials with
ypertriglyceridemia (26,30,31,38,42,51,58,61,74,75); 9 tri-
ls in subjects with coronary artery disease (6,16,47,48,54,
5,64,71,73); and 2 trials in subjects with peripheral arterial
isease (48,68). Other rare study populations included
ealthy subjects (45), type 1 diabetics (53), renal failure (35),
nd cholelithiasis patients (22).
ffects of fibrate on lipids. Fibrate treatment induced
ignificant reductions in serum concentrations of TC, TG, and
DL-C, whereas HDL-C levels were increased (Table 3).
he net change in TC was a decrease of 25.5 mg/dl (0.66
mol/l) (95% confidence interval29.34 to21.66 mg/dl, p
0.00001) or 11%. Of the 53 trials, 52 trials (98%) reported
net decrease, and 1 trial (17) (2%) reported a net increase in
C. Although the efficacy of fibrates differed, they all signifi-
antly (p  0.00001) reduced TC: fenofibrate (13%), ciprofi-
rate (13%), bezafibrate (10%), gemfibrozil (9%), and clofi-
rate (7%).
The net change of TG levels was a decrease of 70.5 mg/dl
0.80 mmol/l) (95% confidence interval 79.78 to 61.22
g/dl, p  0.00001) or 36%. All 53 trials reported significant
p  0.00001) reductions of TG levels with the following
istribution: gemfibrozil (48%), ciprofibrate (45%), fenofibrate
40%), bezafibrate (31%), and clofibrate (18%).
The net change of LDL-C levels consisted of a
ecrease of 11.7 mg/dl (0.30 mmol/l) (95% confidence
nterval 17.86 to 5.59 mg/dl, p  0.0002) or 8%.
ezafibrate (13%; p  0.04), fenofibrate (11%; p  0.01),
nd ciprofibrate (8%; p  0.005) significantly reduced
DL-C levels, whereas clofibrate (3%; p  0.53) and
emfibrozil (1%; p  0.68) had no significant effect on
DL-C. From the 48 trials, 38 trials (79%) showed a net
ecrease in LDL-C after treatment with fibrates, whereas
n 6 (13%) and 4 (8%) trials LDL-C increased and
emained unchanged, respectively. All fibrates, with the
xception of clofibrate, significantly (p  0.00001) in-
reased HDL-C concentration by 4.1 mg/dl (0.11
mol/l) (95% confidence interval 3.34 to 4.91 mg/dl) or
0%. Among the different fibrates, bezafibrate (11%),
emfibrozil (11%), fenofibrate (10%), and ciprofibrate
10%) showed substantial increases in HDL-C levels.
rom the 53 trials, only 47 trials reported HDL-C
utcome. A total of 43 from the 47 eligible trials (91%)
howed a net increase of HDL-C levels, whereas 3 trials
6%) with clofibrate and 1 trial with bezafibrate (3%)
howed a decrease in HDL-C.
dverse effects of fibrates. Overall, 33% of subjects receiv-
ng fibrates experienced adverse effects versus 31% of sub-
ects in the control group (relative risk 1.16; 95% confidence
nterval 1.03 to 1.32, p 0.02). A larger number of subjects
xperienced gastrointestinal symptoms in the fibrate drug
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roup (relative risk 1.37; 95% confidence interval 1.10 to
.70, p  0.004). Other adverse effects were skin reactions
ith a prevalence of 30% and 25% in the treatment and
ontrol group, respectively (relative risk 1.03; 95% confi-
ence interval 0.80 to 1.33, p  0.81), musculoskeletal
ymptoms 3% and 5% in the treatment and control groups,
espectively (relative risk 1.23; 95% confidence interval 0.65
o 2.32, p  0.52).
Hepatotoxicity occurred in 6.4% of subjects receiving
able 1. General Characteristics of RCT With Fibric Acid Deriv
Trial
n,
Male/Female
Age,
yrs
BMI,
kg/m2
Do
mg/
iprofibrate
Illingworth et al. (62) 31, 8/23 NA NA 50–
Kontopoulos et al. (63) 60, 53/7 52 NA 10
Subtotal 91, 61/30 52 NA
lofibrate
CDP (54) 2,248 men 30–64 NA 1,80
Cohn et al. (55) 40, NA 49 NA 50
Crouse et al. (56) 18, NA 54 NA 2,00
Daubresse et al.* (57) 22, NA 55 NA 2,00
Rabkin et al.* (21) 16, 12/4 50 25 2,00
Schneider et al.* (58) 67, 34/33 57 NA 1,20
Seplowitz et al. (59) 33, NA NA NA 2,00
Vecchio et al. (60) 160, NA 18–65 NA 2,00
Zelis et al.* (61) 12, 7/5 45 NA 2,00
Subtotal 2,616, 2,301/42 53 25
enofibrate
Brown et al. (28) 227, 153/74 52 NA 30
Cavallero et al. (41) 28 men 52 27 20
Feher et al. (29) 32, 18/14 62 28 20
Genest et al. (30) 20 men 51 28 20
Goldberg et al. (31) 147, 123/24 52 NA 30
Hodgson et al. (32) 36, 27/9 54 NA 20
Knopp et al. (33) 36, 33/3 53 26 30
Krempf et al. (34) 340, 163/177 18–75 25 200–
Levin et al. (35) 28, 23/5 57 30 67–
Mellies et al. (36) 33, 26/7 49 NA 30
Playford et al. (37) 40, NA 54 31 20
Roglans et al.§ (22) 24, NA 61 30 20
Sasaki et al.* (38) 50, 31/19 55 NA 30
DAIS (39) 405, 298/107 57 29 20
Watts et al.* (40) 11 men 46 31 20
Subtotal 1,457, 954/439 55 28
ezafibrate
Alberti et al. (43) 37, NA 55 26 60
Bradford et al. (44) 82 men 52 26 60
De Man et al.* (42) 18, 16/2 49 28 40
Eagles et al.* (45) 16, 8/8 22 23 40
Elkeles et al. (46) 164, 117/47 51 29 40
BIP‡ (47) 3,090, 2,824/266 60 27 40
LEADER (48) 1,568 men 69 NA 40
Mordasini et al. (49) 18, 7/11 57 NA 60
Niort et al. (50) 36, 18/18 47 27 40
Pazzucconi et al.* (51) 12, 8/4 NA NA 40
Roglans et al.§ (22) 24, NA 61 30 40
BECAIT (52) 81, NA 43 26 60
Winnocour et al. (53) 31, 21/10 50 26 40
Subtotal 5,177, 4,669/366 62 27brates versus 6.1% in the control group (relative risk 1.23; t5% confidence interval 0.98 to 1.53, p  0.07). Serious
dverse effects occurred in 12% versus 13% of patients,
espectively (relative risk 1.02; 95% confidence interval 0.88
o 1.17, p  0.83), whereas cancer prevalence was 4.1%
ersus 3.7% of subjects (relative risk 0.93; 95% confidence
nterval 0.80 to 1.08, p  0.35). Subject withdrawal was
imilar (15%) between the treatment and the control group.
here was no significant difference in adverse effects be-
ween the different fibrates.
ffects of fibrates on coronary end points. Eight long-
s
Duration,
weeks
Study
Population
TC,
mg/dl
TG,
mg/dl
LDL,
mg/dl
HDL,
mg/dl
6 HC & FCH 324 131 249 49
12 FCH 283 284 167 34
18 297 232 195 39
312 CAD 250 266 NA NA
52 CAD 255 191 NA NA
24 HC 326 129 248 42
8 DM type 2 216 184 NA NA
12 FCH 275 305 169 35
4 HC, FCH, & HTG 241 403 NA NA
36 HC 324 110 256 51
24 HC 313 130 236 50
4 HTG 270 429 NA NA
476 259 261 235 48
24 HC & FCH 306 193 217 48
16 DM type 2 196 198 123 34
12 DM type 2 290 275 182 46
8 HTG 222 293 131 27
8 DM type 2 & HTG 261 614 110 31
12 DM type 2 209 217 130 38
24 HC, FCH 293 185 209 49
12 HC 306 138 225 54
24 RF 246 390 143 37
24 HC 306 193 225 43
12 DM type 2 209 208 126 38
8 Cholelith. 241 142 157 63
8 DM2, FCH, & HTG 241 431 119 40
158 DM type 2 215 226 132 40
5 MS 227 215 152 36
355 262 247 170 44
12 DM type 2 242 176 162 46
12 DM2, HC, & FCH 266 244 173 37
6 HTG 302 904 101 29
3 Healthy subjects 182 106 108 NA
156 DM type 2 220 192 148 38
322 CAD 213 145 149 35
156 PAD 218 213 131 46
12 HC & FCH 325 180 195 40
4 DM type 2 276 266 164 45
8 FCH & HTG 271 368 157 43
8 Cholelith. 253 264 165 63
260 CAD NA 145 179 40
12 DM type 1 & HC 278 129 205 55
971 211 178 145 39
Continued on next pageative
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nary events and 675 coronary deaths occurred in subjects in
he control group, whereas 892 events and 398 deaths
ccurred in those allocated to active treatment (Table 4).
ooled results indicated significant reductions in the risk for
ajor coronary events (p  0.001), but not for coronary
eaths. Treatment with fibrates reduced risk of major
oronary events by 25% (95% confidence interval 11% to
7%, p  0.001). Only the Veterans Affairs High-Density
ipoprotein Intervention trial (VA-HIT) and the Helsinki
eart Study (HHS) showed statistically significant reduc-
ions in major coronary events (p  0.001). Other long-
erm trials (i.e., Bezafibrate Coronary Atherosclerosis Inter-
ention trial, Bezafibrate Infarction Prevention study, and
ezafibrate treatment in the Lower Extremity Arterial
isease Event Reduction trial) exhibited tendencies toward
statistically significant (p  0.07) reduction in major
oronary events. No statistically significant reductions were
ound in mortality due to coronary cause or all-cause (Table
). The NNT for all fibrates to prevent one major coronary
vent was 33 for four years. Noncardiovascular mortality was
imilar in active treatment and control groups (relative risk
.10; 95% confidence interval 0.96 to 1.26, p  0.18). The
otal number of enrolled women was 373 compared with
3,945 men.
ffects of niacin on lipids. Niacin treatment was associ-
ted with significant reductions in serum concentrations of
C, TG, LDL-C, and HDL-C (Table 5). The net change
able 1 Continued
Trial
n,
Male/Female
Age,
yrs
BMI,
kg/m2
Do
mg/
emfibrozil
Dumont et al. (13) 64 men 46 31 1,2
HHS (5) 4,081 men 47 27 1,2
LOCAT (14) 595 men 59 27 1,2
Kahri et al. (15) 20, 18/2 56 27 1,2
Knipscheer et al. (16) 33 men 49 NA 1,2
Lahdenpera et al. (17) 16, 14/2 55 27 1,2
Leaf et al.* (18) 13, 7/6 49 NA 1,2
Miller et al.* (19) 14 men 35 NA 1,2
O’Neal et al. (20) 26, 17/9 58 32 1,2
Rabkin et al.* (21) 16, 12/4 50 25 1,2
VA-HIT (4) 2,531 men 64 29 1,2
Roglans et al.§ (22) 24, NA 61 30 9
Vanhanen et al. (23) 19, 10/9 56 28 1,2
Wiklund et al. (24) 137, 91/46 54 26 1,2
Yoshida et al. (25) 19, 10/9 55 25 9
Yuan et al.* (26) 18, 16/2 48 29 1,2
Zambon et al.* (27) 35, 26/9 53 28 1,2
Subtotal 7,461, 7,339/98 54 28
ooled 16,802, 15,330/982 56 27
Crossover design; †micronized fenofibrate; ‡baseline SD was used as an estimate of
erivatives. To convert values for cholesterol to mm/l, multiply by 0.02586; to conve
BECAIT Bezafibrate Coronary Atherosclerosis Intervention trial; BIP Bezafi
ABG  coronary artery bypass grafting; CDP  Coronary Drug Project; cholelith
ellitus; (F) CH  (familial) combined hyperlipidemia; HC  hypercholesterolemi
ypertriglyceridemia; LDL  low density lipoprotein cholesterol; LEADER  Low
rial; NA  not available; PAD  peripheral arterial disease; RCT  randomized c
Veterans Affairs High-Density Lipoprotein Intervention trial; Y&O  young andf TC levels was a decrease of 25.5 mg/dl (0.66 mmol/l) 795% confidence interval 31.80 to 19.13 mg/dl, p 
.00001), corresponding with 10%. Of the 27 trials with TC
utcome, 22 trials (81%) reported a net decrease, and 5 trials
19%) reported a net increase of TC. The SR-niacin and
R-niacin formulations were most effective with a 15% and
3% decrease in TC, respectively.
The net change of TG levels consisted of a decrease of
7.0 mg/dl (0.53 mmol/l) (95% confidence interval 60.72
o 34.67 mg/dl, p  0.00001), corresponding with 20%.
total of 25 trials (86%) reported a net decrease, and 4
rials (14%) reported an increase of TG levels from a total of
9 trials. Among all the niacin formulations, IR-niacin and
R-niacin showed the most substantial reductions of TG
evels of 26% and 20%, respectively.
The net change of LDL-C levels was a decrease of 20.6
g/dl (0.53 mmol/l) (95% confidence interval 28.24 to
13.02 mg/dl, p  0.00001), corresponding with 12%.
he SR-niacin, IR-niacin, and ER-niacin showed signif-
cant reductions of LDL-C concentration of 19%, 15%,
nd 10%, respectively. Acipimox was the only drug
ssociated with a mean increase of LDL-C of approxi-
ately 3% (p  0.60).
Niacin treatment significantly increased HDL-C with
.7 mg/dl (0.17 mmol/l) (95% confidence interval 5.10 to
.44 mg/dl, p  0.00001), or 16%. Among the different
iacin formulations, IR-niacin (23%), ER-niacin (22%),
nd SR-niacin (13%) had the strongest HDL-increasing
apacity (p  0.00001), whereas acipimox only induced a
Duration,
weeks
Study
Population
TC,
mg/dl
TG,
mg/dl
LDL,
mg/dl
HDL,
mg/dl
24 Obesity 218 230 145 33
260 HC 289 176 162 47
128 Post-CABG 200 140 145 32
12 DM type 2 NA NA NA 43
12 CAD 270 322 187 31
12 DM type 2 226 275 130 43
8 DM type 2 472 2,502 NA 23
12 Low HDL-C 147 101 93 34
24 DM type 2 240 350 141 33
12 FCH 275 305 169 35
265 CAD 175 161 112 32
8 Cholelith. 251 149 163 60
12 HC 292 174 181 48
12 HC 282 156 195 48
8 HC 256 218 179 43
6 HTG & HC 247 269 170 40
8 FCH 292 290 200 37
823 242 174 144 41
2,643 237 194 148 41
of the follow-up; §trial had different treatment arms with more than one fibric acid
es for triglycerides to mm/l, multiply by 0.01129.
nfarction Prevention trial; BMI body mass index; CAD coronary artery disease;
holelithiasis; DAIS  Diabetes Atherosclerosis Intervention study; DM  diabetes
L  high-density lipoprotein cholesterol; HHS  Helsinki Heart Study; HTG 
emity Arterial Disease Event Reduction; LOCAT  Lopid Coronary Angiography
led trial; RF  renal failure; TC  total cholesterol; TG  triglycerides; VA-HIT
ubjects.se,
day
00
00
00
00
00
00
00
00
00
00
00
00
00
00
00
00
00
the SD
rt valu
brate I
.  c
a; HD
er Extr% increase (p  0.10). From the 25 trials, 21 trials (84%)
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16%) (3 with acipimox and 1 with SR-niacin) reported a
light decrease in HDL-C concentration.
dverse effects of niacin therapy. Because the high drop-
ut rate (75%) of the largest IR-niacin trial would dominate
he outcome of the safety analysis (54) compared with newer
iacin formulations, we did not pool safety data of this trial
ith other niacin formulations. The most common adverse
ffect in subjects who received niacin was skin flushing.
verall, 70% of subjects receiving niacin experienced
ushes, in contrast with 4% of subjects who received placebo
able 2. General Characteristics of RCT With Nicotinic Acid D
Trial
n,
Male/Female
Age,
yrs
BMI,
kg/m2
Dose
mg/da
R-niacin
Brown et al.‡ (64) 29 men 49 27 2,000
CDP (54) 2,248 men 30–64 NA 1,800
Garg et al.* (65) 13 men 59 30 4,500
King et al.*† (66) 28 men 60 NA 1,500
Knopp et al.‡ (67) 109, 111/36 55 28 1,500–3,
ADMIT study (68) 468, 432/36 66 28 3,000
Mostaza et al.* (69) 13, NA 38–69 24–36 1,500–3,
Vega et al.* (70) 61 men 59 28 4,500
Wink et al. (71) 38, 23/15 63 NA 100
O’Kane et al.‡ (72) 16, NA 52 26 3,000
O’Keefe et al.† (73) 39, NA NA NA 3,000
Subtotal 3,062, 2,945/87 62 28
R-niacin
Aronov et al.* (88) 89, 71/18 50 27 1,500–2,
Keenan et al. (89) 201, NA 50 27 1,000–2,
Vacek et al. (90) 25, 17/8 59 NA 1,200
Keenan et al. (92) 158, 106/61 20–70 NA 1,000–2,
Lavie et al.† (91) 34 men NA NA 3,000
Brown et al.‡ (64) 29 men 49 27 2,000
Subtotal 536, 257/87 46 27
R-niacin
Davignon et al. (85) 79, 55/24 50 NA 1,000–2,
Knopp et al.‡ (67) 149, 113/36 54 28 1,500
Morgan et al. (86) 122, 78/44 52 28 1,000–2,
Goldberg et al. (87) 131, 77/54 54 28 1,000–3,
Grundy et al. (83) 146, 86/60 60 33 1,000–1,
Kuvin et al. (84) 21, 17/4 63 NA 1,500
Subtotal 648, 426/222 55 29
cipimox
Ball et al. (74) 52, 44/10 36–63 NA 750
Crepaldi et al. (75) 130, 85/45 48 26 750–1,
Davoren et al. (76) 60, 43/17 60 28 500
Dean et al. (77) 48, 32/16 56 NA 750
Fulcher et al.*† (78) 30, 25/5 59 26 750
Koev et al. (79) 121, 60/61 56 27 750
O’Kane et al.‡ (72) 21, NA 52 26 750
Otto et al. (80) 18, 11/7 49 27 500–75
Taskinen et al.* (81) 11 men 41 NA 750–1,
Vaag et al. (82) 12, 10/2 58 30 750
Subtotal 503, 321/163 48 27
ooled 4,749, 3,949/559 58 28
Crossover design; †control group was dietary; ‡trial had different treatment arms with
y 0.02586; to convert values for triglycerides to mm/l, multiply by 0.01129.
ER-niacin  extended-release niacin; IR-niacin  immediate-release niacin; S
bbreviations as in Table 1.relative risk 7; 95% confidence interval 3.98 to 12.26, p  2.00001). The distribution of flushes in the various niacin
ormulations showed that subjects with IR-niacin had the
ighest prevalence of flushing up to 85% (relative risk 14;
5% CI 4.94 to 38.90). Other formulations with a high rate
f flushes included ER-niacin 66% (relative risk 5; 95%
onfidence interval 3.36 to 7.51), whereas flushes seemed to
ccur less in SR-niacin (26%) and acipimox (22%). Flushing
as the main reason for subject withdrawal.
Approximately 13% of the subjects in the niacin group
ithdrew from the study, compared with 6% in the placebo
roup (relative risk 1.87; 95% confidence interval 1.19 to
tives
Duration,
weeks
Study
Population
TC,
mg/dl
TG,
mg/dl
LDL,
mg/dl
HDL,
mg/dl
112 CAD 299 191 215 46
312 CAD 250 266 NA NA
8 DM type 2 259 450 131 29
12 Healthy 192 197 123 32
16 HC 276 158 200 45
60 DM2 & PAD 213 176 137 41
8 CH 264 322 163 33
8 Low HDL-C 194 147 122 32
12 CAD 193 182 111 47
12 FCH 338 270 232 52
18 CAD 228 287 134 36
578 244 243 147 41
16 HC 278 171 198 46
8 HC 264 144 184 50
12 HC 277 173 209 45
8 HC (Y&O) 261 149 182 49
12 Low HDL & CAD 196 205 142 26
64 CAD 299 191 215 46
120 264 158 186 47
8 HC 314 176 233 45
16 HC 276 158 200 45
16 HC 274 147 201 43
26 HC 300 191 216 45
16 DM type 2 NA 268 103 41
12 Low LDL & CAD 143 192 72 36
94 282 191 170 43
12 FCH & HTG 302 412 NA 45
8 HC, FCH & HTG 284 322 185 39
12 DM type 2 216 190 NA 43
12 DM type 2 253 261 160 44
12 DM type 2 242 258 155 39
12 DM type 2 268 264 NA 44
12 FCH 338 270 232 52
24 CH 350 292 238 43
8 DM2 & HTG 247 593 107 NA
12 DM type 2 230 222 154 38
124 271 292 180 43
916 262 239 167 43
than one nicotinic acid derivatives. To convert values for cholesterol to mm/l multiply
in  wax-matrix sustained-release niacin; Y-O  young and old subjects; othereriva
,
y
000
000
000
000
000
000
000
000
500
200
0
200
more
R-niac.93, p  0.006). The subject withdrawal rate was distrib-
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January 18, 2005:185–97 Efficacy and Safety of HDL-C-Increasing Compoundsted as follows: IR-niacin (20.2% in the niacin group vs.
.6% in the control group), ER-niacin (19.7% vs. 10.2%),
cipimox (4.3% vs. 4.6%), and SR-niacin (2.9% vs. 0%),
espectively; IR-niacin had the highest prevalence for sub-
ect withdrawal (relative risk 4.06; 95% confidence interval
.44 to 11.44, p  0.008). The relative risk for subject
ithdrawal during ER-niacin was lower than during IR-
iacin (relative risk 1.51; 95% confidence interval 0.63 to
.61, p  0.35).
Gastrointestinal symptoms had a prevalence of 23% and
5% in the treatment and control group, respectively (rela-
ive risk 1.57; 95% confidence interval 1.05 to 2.34, p 
.03) ER-niacin 35% vs. 24% (relative risk 1.95; 95%
onfidence interval 0.91 to 4.14, p  0.08); IR-niacin 20%
s. 20% (relative risk 1.24: 95% confidence interval 0.47 to
.29, p  0.66); SR-niacin 15% vs. 5% (relative risk 5.21;
5% confidence interval 0.36 to 75.18, p  0.23); and
cipimox 11% vs. 8% (relative risk 1.48; 95% confidence
nterval 0.79 to 2.78, p  0.22). Other adverse effects were
kin reactions, 11% and 5% (relative risk 2.71; 95% confi-
ence interval 1.48 to 4.97, p 0.001), and musculoskeletal
Table 3. Net Change in Serum Lipids Concen
Derivatives as Compared With the Control Gr
Index
No. of
Trials
No. of
Subjects
Total cholesterol
Bezafibrate 13* 5,177
Ciprofibrate 2 91
Clofibrate 8 2,616
Fenofibrate 15* 1,457
Gemfibrozil 16* 7,441
Pooled 54 16,782
Triglycerides
Bezafibrate 13* 5,177
Ciprofibrate 2 91
Clofibrate 7 2,582
Fenofibrate 15* 1,457
Gemfibrozil 16* 7,441
Pooled 53 16,748
LDL cholesterol
Bezafibrate 13* 5,177
Ciprofibrate 2 91
Clofibrate 4 278
Fenofibrate 15* 1,457
Gemfibrozil 15* 7,428
Pooled 49 14,431
HDL cholesterol
Bezafibrate 12* 5,161
Ciprofibrate 2 91
Clofibrate 4 278
Fenofibrate 15* 1,457
Gemfibrozil 17* 7,461
Pooled 50 14,448
*No. of trials includes trials with more than one fibric acid t
by 0.02586; to convert values for triglycerides to mm/l, multi
treatment minus the change during control.
CI  confidence interval; HDL  high-density lipoprotymptoms, 1% and 0.1% (relative risk 2.87: 95% confidence Snterval 0.49 to 16.91, p  0.24), respectively. Hepatotox-
city occurred in 2.1% of subjects receiving niacin versus
.3% in the control group (relative risk 3.15; 95% confi-
ence interval 1.85 to 7.85, p  0.01).
Hyperglycemia had an occurrence rate of 2.3% versus
.4% in the niacin and the control group, respectively
relative risk 3.04; 95% confidence interval 1.28 to 7.21, p
.01). From all the niacin derivatives, ER-niacin and
R-niacin had the highest prevalence of, respectively, 4%
relative risk 5.67; 95% confidence interval 1.06 to 30.30,
 0.04) and 2.3% (relative risk 2.79; 95% confidence
nterval 0.89 to 8.73, p  0.08).
ensitivity and subgroup analysis. Comparison of the
xed-effects with the random-effects model resulted in
omparable changes for lipid efficacy. For fibrates, the
umbers were 15 versus 25 mg/dl for TC, 51 versus
70 mg/dl for TG, 13 versus 12 mg/dl for LDL-C,
nd 4 versus 4 mg/dl for HDL-C, respectively. The
umbers for niacin were 24 versus 25 mg/dl for TC,
36 versus 47 mg/dl for TG, 20 versus 21 mg/dl for
DL-C, 7 versus 7 mg/dl for HDL-C, respectively.
n in Subjects Treated With Fibric Acid
t Change
(mg/dl)
95% CI
(Random)
Percent
Change
21.4 27.59 to 15.11 10.1
36.9 52.59 to 21.21 12.6
16.8 19.87 to 13.68 6.5
34.9 46.50 to 23.35 13.3
21.3 28.78 to 13.90 8.8
25.5 29.34 to 21.66 10.8
54.7 69.54 to 39.83 30.7
104.3 171.06 to 37.56 45.0
46.6 63.94 to 29.31 17.9
99.0 130.04 to67.97 40.1
83.3 99.92 to 66.58 47.9
70.5 79.78 to 61.22 36.3
18.1 35.22 to 0.93 12.5
15.9 27.00 to 4.83 8.4
7.3 30.01 to 15.46 3.1
17.8 32.06 to 3.48 10.5
1.7 9.74 to 6.35 1.2
11.7 17.86 to 5.59 7.8
4.3 3.35 to 5.15 11.0
3.9 2.27 to 5.52 10.0
0.1 3.11 to 2.99 0.2
4.5 3.24 to 5.74 10.2
4.4 2.98 to 5.86 10.7
4.1 3.34 to 4.91 10.0
nt arm. To convert values for cholesterol to mm/l, multiply
0.01129; net change is expressed as the change during active
DL  low-density lipoprotein.tratio
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ined hyperlipidemia, type II diabetes mellitus, and low
DL-C showed moderate differences (Table 6).
ISCUSSION
tatin therapy has been accepted as standard therapy to
ower CV risk. However, because the majority of CV events
annot be prevented with statins (2), despite their extensive
DL-lowering and weak HDL-increasing (5%) properties,
his has prompted us to focus the present analysis on efficacy
nd safety of HDL-increasing compounds offering the
otential for future combination therapy. The choice for
DL-increasing strategies as second target after LDL-
owering reflects both solid epidemiologic data as well as the
dvent of numerous options for selective HDL-increase
ithin the next few years. To date, two compounds,
urrently available for clinical use, fit this profile: fibric acid
nd nicotinic acid derivatives.
ipid profile changes. A consistent HDL-increasing effect
able 4. Risk Reduction for Major Coronary Events and Deaths
No. of Events
Control Fibrate
Relative Risk Red
% (95% CI
ajor coronary events 1,609 892 25 (10 to 38)
CDP, 1975 (54) 839 309 9 (3 to 20
HHS, 1987 (5) 84 56 30 (5 to 48)
BECAIT, 1997 (52) 11 3 25 (16 to 92)
LOCAT, 1997, (14) 7 7 1 (181 to
BIP, 2000 (47) 232 211 9 (8 to 24
VA-HIT, 2001 (4) 275 219 20 (6 to 32)
LEADER, 2002 (48) 111 49 56 (39 to 68)
DAIS, 2003 (39) 50 38 21 (16 to 4
oronary deaths 675 398 10 (2 to 20
CDP 392 135 13 (5 to 27
HHS 12 11 9 (105 to
BIP 88 95 8 (42 to 1
VA-HIT 118 93 21 (2 to 39
LEADER 65 64 1 (37 to 2
ardiovascular deaths 840 480 8 (3 to 18
CDP 528 191 9 (6 to 21
HHS 23 21 98 (556 to
BIP 88 95 8 (42 to 1
VA-HIT 127 96 67 (23 to 8
LEADER 74 77 4 (41 to 2
oncardiovascular deaths 348 344 7 (24 to 7
CDP 42 23 38 (129 to
HHS 19 23 20 (119 to
BIP 64 66 3 (44 to 2
VA-HIT 93 102 10 (44 to 1
LEADER 121 127 5 (32 to 1
ll-cause deaths 1,201 835 2 (7 to 10
CDP 583 221 4 (10 to 1
HHS 42 45 6 (61 to 3
BIP 152 161 5 (24 to 1
VA-HIT 220 198 10 (8 to 24
LEADER 195 204 5 (20 to 8
DAIS 9 6 30 (92 to 7
ajor coronary events included coronary death, definite nonfatal myocardial infarcti
CI  confidence interval; other abbreviations as in Table 1.f approximately 10% was found for fibrates. This effect was sore pronounced in patients with combined hyperlipidemia
nd/or hypercholesterolemia ranging from 11% up to 16%.
he HDL increase by niacin exceeded that of fibrate
herapy approximately 1.6-fold, ranging from 7% up to
3%. The effects of IR-niacin (23%) and ER-niacin (22%)
ere more pronounced than those observed during SR-
iacin (13%) or acipimox (7%) therapy. Of note, the
onsistency of this observation seriously questions the use of
he latter compounds as a means of achieving HDL
ncreases.
With regard to TG, significant reductions were achieved
y all fibrates, ranging from 18% up to 48%. This effect of
brates was consistent throughout the different forms of
yslipidemia included in the present analysis. The efficacy of
iacin or its derivatives toward TG lowering was less pro-
ounced when compared with fibrate therapy, ranging from
7% to 26%. The reductions in TC and LDL-C during fibrate
herapy ranged between 7% and 13% and 8% and 13%,
espectively. Niacin and its derivatives were shown to be
Coronary Disease, Cardiovascular Disease
n, Absolute Risk Reduction
per 1,000 (95% CI)
No. Needed to Treat
(95% CI) p Value
30 (10 to 50)  33 (20–100) 0.00120 (10 to 50) 0.1310 (0 to 30) 0.001210 (50 to 370) 0.070 (40 to 40) 0.00110 (10 to 40) 0.07
40 (10 to 70) 0.001
80 (50 to 110) 0.07
50 (30 to 130) 0.23
10 (0 to 10)  100 (0–100) 0.1020 (10 to 40) 0.140 (10 to 10) 0.080 (20 to 10) 0.73
20 (0 to 40) 0.08
0 (30 to 30) 0.73
0 (10 to 10)  — 0.3920 (10 to 40) 0.240 (10 to 0) 0.680 (20 to 10) 0.58
0 (0 to 10) 0.68
0 (30 to 30) 0.58
0 (10 to 0)  — 0.3310 (20 to 0) 0.210 (10 to 0) 0.640 (20 to 10) 0.66
0 (20 to 20) 0.64
10 (40 to 30) 0.66
0 (10 to 10)  — 0.6610 (20 to 40) 0.550 (10 to 10) 0.3610 (30 to 20) 0.4620 (10 to 50) 0.36
10 (60 to 30) 0.46
10 (20 to 50) 0.49
d silent myocardial infarction.From
uctio
)
)
64)
)
5)
)
)
60)
9)
)
9)
)
)
40)
9)
1)
3)
)
16)
35)
7)
6)
6)
)
7)
0)
1)
)
)
5)lightly more effective in reducing LDL-C levels than fibrates.
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January 18, 2005:185–97 Efficacy and Safety of HDL-C-Increasing Compoundsafety. The incidence of adverse effects in subjects receiv-
ng fibrates was increased compared with placebo (relative
isk 1.16, p  0.02). The most common side effects during
brate therapy were skin reactions (30%) and gastrointesti-
al symptoms (12%). Other adverse events like hepatotox-
city (6%) and musculoskeletal symptoms (3%) occurred
uch less frequently. The withdrawal rate from the trials
as 15% in both the fibrate and the placebo group. Previous
eports have addressed concerns with regard to using fi-
rates in view of a potential increase in the risk of death
rom noncoronary causes and/or the induction of cancer
93). In the present meta-analysis, we could not find any
ncrease in noncoronary mortality and/or the prevalence of
ancer. Notably, in view of the predefined inclusion criteria
or studies with regard to available lipid profile data and
reatment arms with the combination of both drugs, we
Table 5. Net Change in Serum Lipids Concen
Derivatives as Compared With the Control Gr
Index
No. of
Trials
No. of
Subjects
Total cholesterol
Acipimox 10* 503
ER-niacin 5* 502
IR-niacin 11* 3,062
SR-niacin 6* 536
Pooled 32 4,603
Triglycerides
Acipimox 10* 503
ER-niacin 6* 648
IR-niacin 11* 3,062
SR-niacin 6* 536
Pooled 33* 4,749
LDL cholesterol
Acipimox 7* 270
ER-niacin 6* 648
IR-niacin 10* 814
SR-niacin 6* 536
Pooled 29 2,268
HDL cholesterol
Acipimox 9* 492
ER-niacin 6* 648
IR-niacin 10* 814
SR-niacin 6* 536
Pooled 29 2,490
*No. of trials includes trials with more than one fibric acid t
by 0.02586; to convert values for triglycerides to mm/l, multi
treatment minus the change during control. To convert valu
for triglycerides to mm/l, multiply by 0.01129.
CI  confidence interval; other abbreviations as in Table
able 6. Subgroup Analysis With Net Change in mg/dl of Fibric
opulations
Fibric Acid Derivatives
No. of Trials TC TG L
ll trials 53 26 71 
ypercholesterolemia 19 33 64 
ombined hyperlipidemia 11 38 89 
iabetes mellitus type 2 9 24 114
ow HDL-C 21 20 102bbreviations as in Table 1.ere unable to include the data from the World Health
rganization cooperative trial on primary prevention of
HD by clofibrate. Because adverse effects on overall
ortality in previous analyses were largely explained by the
esults of the latter study, it is in line with expectations that
e did not find a negative effect. In view of the large number
f subjects included in the present meta-analysis, it appears
afe to conclude that fibrate therapy is well-tolerated with-
ut conveying additional risks.
As expected, flushes were the most common adverse
ffect with niacin. Most studies, however, report a decline in
he incidence of flushing during prolonged use. Although
he SR-niacin and acipimox formulations had a lower
ncidence of flushes, the HDL-raising efficacy of these
ompounds is significantly less than the other compounds.
here was also a modest increase in gastrointestinal symp-
n in Subjects Treated With Nicotinic Acid
t Change
mg/dl) 95% CI (Random)
Percent
Change
9.4 21.97 to 3.11 3.5
20.8 33.92 to 7.61 7.4
30.7 41.26 to 20.05 12.6
38.6 49.02 to 28.18 14.6
25.5 31.80 to 19.13 9.7
66.4 109.83 to22.96 22.7
37.2 53.65 to 20.72 19.5
64.0 77.92 to 50.16 26.4
27.1 32.27 to 21.95 17.2
46.9 60.72 to 34.67 20.0
5.1 14.08 to 24.21 2.8
16.2 25.06 to 7.40 9.5
22.7 34.75 to 10.64 15.4
37.5 46.63 to 28.40 19.1
20.63 28.24 to 13.02 12.4
3.0 0.58 to 6.57 7.0
9.2 6.96 to 11.42 21.9
9.2 8.56 to 9.91 22.5
6.0 5.15 to 6.74 12.7
6.7 5.10 to 8.44 15.7
nt arm. To convert values for cholesterol to mm/l, multiply
0.01129; net change is expressed as the change during active
cholesterol to mm/l, multiply by 0.02586; to convert values
d 2.
d Derivatives and Nicotinic Acid Derivatives in Different Study
Nicotinic Acid Derivatives
HDL No. of Trials TC TG LDL HDL
4 30 26 47 21 7
4 10 31 40 31 6
4 5 17 54 3 4
4 16 21 92 9 8
4 10 18 63 4 7tratio
oup
Ne
(













reatme
ply by
es forAci
DL
12
20
17
7
4
t
c
s
b
m
t
s
c
e
m
o
A
s
r
C
o
e
C
c
H
i
2
g
m
(
s
p
fi
m
t
t
a
a
D
v
p
c
t
t
c
T
t
f
o
i
s
a
t
c
r
4
r
r
b
1
r
a
o
c
t
r
s
s
w
S
T
B
i
m
o
t
s
c
c
h
d
p
r
t
f
u
e
C
c
p
n
p
s
p
H
u
i
c
(
r
i
a
p
r
i
i
L
B
a
l
i
r
i
194 Birjmohun et al. JACC Vol. 45, No. 2, 2005
Efficacy and Safety of HDL-C-Increasing Compounds January 18, 2005:185–97oms in the niacin group (23%) when compared with the
ontrol group (15%). We found relatively little evidence to
upport the concerns for hepatotoxicity with SR-niacin,
ecause only two of six trials with SR-niacin reported
odest elevations of liver enzymes (90,91). Although niacin
reatment has been associated with worsening of insulin
ensitivity (assessed using euglycemic, hyperinsulinemic
lamp technique), only few subjects experienced this side-
ffect (2%). More importantly, potential changes in glyce-
ic control did not result in a need to change the regimen
f diabetic control. These findings are consistent with the
rterial Disease Multiple Intervention Trial (ADMIT)
tudy, in which glycemic control was affected only tempo-
arily by IR-niacin therapy in 125 diabetics (68).
V outcome. In contrast with the overwhelming number
f patients included in statin studies, the number of studies
valuating the effect of fibrates and/or niacin derivatives on
V outcome is limited. Two crucial studies with fibrates
omprise the VA-HIT study and the HHS. In the VA-
IT study, the primary end point (nonfatal myocardial
nfarction or coronary death) frequency was reduced from
1.7% in the control group to 17.3% in the gemfibrozil
roup, whereas the HDL increase upon gemfibrozil treat-
ent largely predicted CV benefit in multivariate analysis
94). In the HHS, the primary end point (CHD events) was
ignificantly reduced in the gemfibrozil group (2.7%), com-
ared with the control group (4.1%). Other studies using
brate therapy have yielded less convincing results (Table 4),
ost likely related to power and patient selection. It remains
o be established whether and to what extent the combina-
ion of statins and fibrates confers additive protection
gainst CHD. Currently, two studies addressing this issue
re the Fenofibrate Intervention and Event Lowering in
iabetes (FIELD) trial and the Action to Control Cardio-
ascular Risk in Diabetes (ACCORD) trial.
The previously reported interaction between fibrates,
articularly gemfibrozil, and statins asks for some degree of
aution while implementing combination therapy with
hese compounds (95).
The number of studies addressing the effect of mono-
herapy with nicotinic acid derivatives on CV event out-
omes is limited to one study, the coronary drug project.
his study reported a modest 11% reduction of CV mor-
ality and a 27% reduction of major coronary events after a
ollow-up period as long as 10 years (54). However, the use
f immediate-release preparations in that study, character-
zed by multiple daily dosing and a large number of
ide-effects, resulted in a dropout rate larger than 70% in
ddition to not-quantified effects due to noncompliance. In
his respect, two recent smaller trials evaluating niacin
ombined with either a bile acid sequestrant or a statin
eported impressive HDL increases ranging from 25% to
1% with an unprecedented reduction of CV event rates
anging from 60% to 72% (9,10). Notably, these impressive
eduction rates fit nicely to the estimated reduction rates
ased on the obtained HDL increase in these studies (i.e., p% HDL increase being associated with a 1% to 3%
eduction in CV events [94]). These data warrant longer
nd adequately powered studies to verify these promising
bservations. In line with these results, the combination of
lofibrate and niacin showed impressive reductions of 36%
o 60% (p  0.01) in CV mortality, which was directly
elated to serum TG-lowering in the Stockholm Heart
tudy (96). Unfortunately, in view of the predefined inclu-
ion criteria for studies with regard to the treatment arm, we
ere unable to include the data from this study.
tudy limitations. Most studies did not report the SDdifference.
his was the most common reason to contact the authors.
ecause the response rate and data availability was disappoint-
ng, we had to calculate the SDdifference with the formula
entioned in the Methods section. This resulted in a slightly
verestimated SDdifference, which in turn, marginally decreased
he weight of the studies. Although this is not the ideal
ituation, this formula provides a generally accepted method to
alculate the SDdifference. Another issue is the weighing of
ontinuous data, which is in favor of small studies with
omogeneous populations upon pooling of all studies with
ifferent numbers of subjects, dyslipidemias, and agents. In the
resent analyses, we limited this phenomenon by applying a
andom-effects model.
It must also be noted that, in almost all fibrate interven-
ion trials, mostly men were included, with a male-to-
emale ratio of 16:1. Awaiting ongoing combination trials
sing statins and fibrates, one has to be careful before
xtrapolating all findings toward female patients.
linical perspectives. The global epidemic of CHD in
ombination with the inability of statin monotherapy to
revent more than 25% to 30% of CV events emphasizes the
eed for combination therapies; HDL increase offers a
romising target for future CV prevention trials. First,
trong observational studies validate the antiatherogenic
otential of HDL-C. Second, the prognostic value of
DL-C on CV outcome remains present, even in patients
sing statin therapy (97). Third, the currently available
ntervention studies with niacin support an additive benefi-
ial effect of these compounds on top of statin therapy
9,10), and we believe that fibrates may also add to event
eduction in combination with statins. Finally, new HDL-
ncreasing strategies with weekly apoAI-Milano infusions
re able to induce a 4.2% reduction in plaque volume in a
eriod of five weeks (98). These findings outperform the
eduction in plaque volume established after 18 months of
ntensive LDL-lowering therapy with 80 mg of atorvastatin
n the Reversal of Atherosclerosis with Aggressive Lipid
owering (REVERSAL) study, reaching only 0.9% (99).
ecause the latter changes might be extrapolated to result in
significant improvement in CV outcome during intensive
ipid-lowering therapy, the expectations for potent HDL
ncrease combined with intensive LDL-lowering have been
aised significantly. The recent reports on significant HDL
ncreases up to 60% during cholesterol ester transfer
rotein-inhibition with 120 mg of torcetrapib (100) might
b
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ion strategy.
In summary, both fibrates and niacin provide a safe and
ffective way of increasing HDL-C, the latter being the
ost potent one. Whereas for both, particularly for fibrates,
ntervention data have emerged to show beneficial effects on
V outcome; their ability to enhance CV event reduction
hen added to statin monotherapy has been shown in small
rials with niacin and may be shown with larger ongoing
rials with fenofibrate.
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